About Index Trending news
Analyze
Pricing
Abingworth

Abingworth

Work at Abingworth? Add yourself to this profile

Abingworth

Abingworth is an international investment group collaborating with life sciences entrepreneurs to develop products that have a dramatic impact on health.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

22 Jun 2016
$27,000,000
Venture capital (Series A)
Added by

Biopharmaceutical Company IFM Therapeutics Closes $27M Series A Financing

FinSMEs
08 Mar 2016
$43,000,000
Venture capital (Series B)
Added by

Tizona Therapeutics Closes $43M Series B Funding

FinSMEs
23 Jul 2015
$22,000,000
Venture capital (Series A)
Abingworth, Roche Venture Fund, CTI Life Sciences Fund, +1
Added by

With $22M Shot of Venture, Sutro Spinout Aims For Better Vaccines

Xconomy
28 Apr 2015
$64,000,000
Venture capital (Series B)
Added by

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

FierceBiotech
27 Feb 2015
$70,000,000
Venture capital (Series E)
16 May 2014
25 Nov 2013
$19,299,000
Venture capital (Series A)
07 Oct 2013
31 Jul 2013
$60,000,000
Venture capital (Series C)
08 Jan 2013
$5,300,000
Venture capital (Series D)
Alloy Ventures, GE Ventures, H&Q Healthcare Investors, +4
23 Jul 2012
$38,500,000
Venture capital (Series D)
28 Mar 2012
$65,000,000
Venture capital (Series C)
12 Sep 2011
18 May 2011
$12,000,000
Venture capital
06 Oct 2010
$30,000,000
Venture capital (Series C)
Advent Venture Partners, Novus Ventures, Venrock, +3
30 Oct 2009
$20,000,000
Venture capital (Series C)
05 Oct 2009
$35,957,968
Venture capital (Series B)